I never said the conference wasn't worthwhile - just that 1AD shouldn't be attending. It is a pointless exercise for them to continually pedal the same pre-clinical story until they have some hard data. The story is 'known' - it just isn't being 'bought' atm. And it annoys we that they are doing so so soon after a somewhat botched capital raising.
On reflection I'll stick with naive indignation.
Ann: AdAlta to present at 2019 Bioshares Biotech Summit, page-4
Add 1AD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
-0.001(3.85%) |
Mkt cap ! $14.89M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.4¢ | $14.58K | 594.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 129101 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 400000 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| 1AD (ASX) Chart |